Busulfan

Generic Name
Busulfan
Brand Names
Busulfex, Myleran, Busulfan Fresenius Kabi
Drug Type
Small Molecule
Chemical Formula
C6H14O6S2
CAS Number
55-98-1
Unique Ingredient Identifier
G1LN9045DK
Background

Busulfan is a bifunctional alkylating agent, having a selective immunosuppressive effect on bone marrow. It is not a structural analog of the nitrogen mustards. It has been used in the palliative treatment of chronic myeloid leukemia (myeloid leukemia, chronic), but although symptomatic relief is provided, no permanent remission is brought about. According t...

Indication

For use in combination with cyclophosphamide as a conditioning regimen prior to allogeneic hematopoietic progenitor cell transplantation for chronic myelogenous (myeloid, myelocytic, granulocytic) leukemia (FDA has designated busulfan as an orphan drug for this use). It is also used as a component of pretransplant conditioning regimens in patients undergoing...

Associated Conditions
Chronic Myelogenous Leukemia (CML), Essential Thrombocythemia (ET), Polycythemia Vera (PV)
Associated Therapies
Conditioning regimens for allogeneic stem cell transplantation therapy
Clinical Trials
Related News

Chemotherapy Plus Peripheral Stem Cell Transplant in Treating Patients Who Have Multiple Myeloma or Primary Systemic Amyloidosis

First Posted Date
2003-01-27
Last Posted Date
2013-02-04
Lead Sponsor
Herbert Irving Comprehensive Cancer Center
Target Recruit Count
75
Registration Number
NCT00007995
Locations
🇺🇸

Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center, New York, New York, United States

Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myelogenous Leukemia or Myelodysplastic Syndrome

Phase 3
Completed
Conditions
Childhood Acute Erythroleukemia (M6)
Childhood Acute Megakaryocytic Leukemia (M7)
Childhood Acute Monoblastic Leukemia (M5a)
Childhood Acute Monocytic Leukemia (M5b)
Childhood Acute Myeloblastic Leukemia With Maturation (M2)
Childhood Acute Myeloblastic Leukemia Without Maturation (M1)
Childhood Acute Myelomonocytic Leukemia (M4)
Childhood Myelodysplastic Syndromes
Chronic Myelomonocytic Leukemia
de Novo Myelodysplastic Syndromes
Interventions
Drug: daunorubicin hydrochloride
Drug: asparaginase
Drug: therapeutic hydrocortisone
Radiation: 3-dimensional conformal radiation therapy
Drug: fludarabine phosphate
Procedure: allogeneic bone marrow transplantation
Biological: filgrastim
Drug: cytarabine
Drug: idarubicin
Drug: dexamethasone
Biological: aldesleukin
Drug: thioguanine
Drug: etoposide
Drug: methotrexate
Drug: cyclophosphamide
Drug: busulfan
First Posted Date
2003-01-27
Last Posted Date
2013-01-16
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
880
Registration Number
NCT00002798
Locations
🇺🇸

Children's Oncology Group, Arcadia, California, United States

Donor Peripheral Stem Cell Transplant in Treating Patients With Myelodysplastic Syndrome, Acute Myeloid Leukemia, or Myeloproliferative Disorder

First Posted Date
2003-01-27
Last Posted Date
2010-09-16
Lead Sponsor
Fred Hutchinson Cancer Center
Target Recruit Count
30
Registration Number
NCT00049634
Locations
🇺🇸

Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

🇺🇸

Seattle Cancer Care Alliance, Seattle, Washington, United States

Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With AML Leukemia

First Posted Date
2003-01-27
Last Posted Date
2023-06-15
Lead Sponsor
Eastern Cooperative Oncology Group
Target Recruit Count
657
Registration Number
NCT00049517
Locations
🇺🇸

Community Medical Center, Missoula, Montana, United States

🇺🇸

Penn State Cancer Institute at Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States

🇺🇸

Mercy and Unity Cancer Center at Mercy Hospital, Coon Rapids, Minnesota, United States

and more 96 locations

Umbilical Cord Blood Transplantation in Treating Patients With High-Risk Hematologic Cancer

First Posted Date
2003-01-27
Last Posted Date
2012-03-15
Lead Sponsor
Case Comprehensive Cancer Center
Target Recruit Count
44
Registration Number
NCT00003335
Locations
🇺🇸

Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer

First Posted Date
2003-01-27
Last Posted Date
2021-08-13
Lead Sponsor
Roswell Park Cancer Institute
Target Recruit Count
361
Registration Number
NCT00003816
Locations
🇺🇸

Roswell Park Cancer Institute, Buffalo, New York, United States

Combination Chemotherapy Followed by Surgery and Peripheral Stem Cell or Bone Marrow Transplantation in Treating Infants With Newly Diagnosed Neuroblastoma

Phase 2
Completed
Conditions
Neuroblastoma
First Posted Date
2003-01-27
Last Posted Date
2013-09-17
Lead Sponsor
European Infant Neuroblastoma Study Group - 1999
Registration Number
NCT00025649
Locations
🇸🇪

Ostra Sjukhuset, Gothenburg, Sweden

🇫🇷

Centre Hospitalier Regional de Purpan, Toulouse, France

🇳🇴

Rikshospitalet University Hospital, Oslo, Norway

and more 8 locations

Chemotherapy and Surgery Followed by Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Neuroblastoma

Phase 2
Conditions
Neuroblastoma
First Posted Date
2003-01-27
Last Posted Date
2013-08-07
Lead Sponsor
Children's Cancer and Leukaemia Group
Registration Number
NCT00024193
Locations
🇫🇷

Institut Gustave Roussy, Villejuif, France

Combination Chemo, Peripheral Stem Cell Transplant, Biological Therapy, Pamidronate and Thalidomide for Multiple Myeloma

First Posted Date
2003-01-27
Last Posted Date
2019-07-02
Lead Sponsor
City of Hope Medical Center
Target Recruit Count
77
Registration Number
NCT00004088
Locations
🇺🇸

Banner Good Samaritan Medical Center, Phoenix, Arizona, United States

🇺🇸

City of Hope Comprehensive Cancer Center, Duarte, California, United States

Combination Chemotherapy and Peripheral Blood Stem Cell Transplant Followed By Aldesleukin and Sargramostim in Treating Patients With Inflammatory Stage IIIB or Metastatic Stage IV Breast Cancer

First Posted Date
2003-01-27
Last Posted Date
2017-07-12
Lead Sponsor
Fred Hutchinson Cancer Center
Target Recruit Count
50
Registration Number
NCT00003199
Locations
🇺🇸

Fred Hutchinson Cancer Research Center/Puget Sound Oncology Consortium, Seattle, Washington, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy